Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status

Abstract

Background The benefit of palliative chemotherapy (PC) in patients with advanced solid tumors and poor performance status (ECOG-PS) has not been prospectively validated, which makes treatment decision challenging. We aimed to evaluate the overall survival, factors associated with early mortality, and adoption of additional procedures in hospitalized patients with advanced cancer and poor ECOG-PS treated with PC. Methods We analyzed a retrospective cohort of patients with advanced cancer treated with PC during hospitalization at an academic cancer center in Brazil from 2014 to 2016. Eligibility criteria included: ECOG-PS 3–4 and start of first-line PC; or ECOG-PS ≥ 2 and start of second or subsequent lines. Primary endpoint was 30-day survival from start of PC. Kaplan-Meier method was used for survival estimates and Cox regression for factors associated with 30-day mortality. Results Two hundred twenty-eight patients were eligible. 21.9, 66.7 and 11.4% of patients had ECOG-PS 2, 3 and 4, respectively. 49.6% had gastrointestinal tumors. Median follow-up was 49 days (range 1–507). 98.2% of patients had died, 32% during the index hospitalization. The 30-day and 60-day survival rates were 55.7 and 38.5%, respectively. 30% of patients were admitted to the intensive care unit. In a multivariable analysis, ECOG-PS 3/4 (HR 2.01; P = 0.016), hypercalcemia (HR 2.19; P = 0.005), and elevated bilirubin (HR 3.17; P < 0.001) were significantly associated with 30-day mortality. Conclusions Patients with advanced cancer and poor ECOG-PS had short survival after treatment with inpatient PC. Inpatient PC was associated with aggressive end-of-life care. Prognostic markers such as ECOG-PS, hypercalcemia and elevated bilirubin can contribute to the decision-making process for these patients.

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

“…As a result, death within 30 days of chemotherapy has been used as a quality indicator for cancer care. [60][61][62] Both ESMO and ASCO have published Recommendations should be implemented in centers of expertise in the specific technique after multidisciplinary review or in the context of a clinical trial. position statements encouraging discussions about the appropriate cessation of chemotherapy; however, implementation of such recommendations has been limited.…”

Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting

“…Prior studies have shown that administering cytotoxic chemotherapy during inpatient admission leads to poor outcomes, including high mortality and aggressive end‐of‐life care; it is unknown whether this is also true for ICI therapy [9]. The absence of data makes it difficult for physicians to identify which inpatients are likely to benefit from initiating ICI therapy.…”

Developing and validating a model for predicting 7-day mortality of patients admitted from the emergency department: an initial alarm score by a prospective prediction model study

“…The presence of underlying active cancer and metastatic status are both important predictors for in-hospital mortality due to their immune-compromised status. 15 The effect of cancer on a patient's outcome has been proven in critical care. 16 17 However, whether patients have cancer with or without metastasis may provide little insight on the poor prognosis, and as high as 25% of terminal cancer patients receive vasopressors in the dying process.…”